Haemonetics signs non-exclusive U.S. plasma supply deal with CSL Plasma for NexSys PCS devices, disposables
HAE•Guidance and transition timing
The companies did not include minimum purchase commitments, and the scope and timing for transitioning U.S. plasma centers remain undetermined.
Haemonetics said fiscal 2027 guidance is unchanged, and it plans to provide an impact update on the second-quarter earnings call in November 2026.
Supply agreement with CSL Plasma
Haemonetics said it signed a non-exclusive U.S. supply agreement with CSL Plasma on Aug. 14, 2026 for NexSys PCS devices.
CSL Plasma can use NexSys PCS with Persona PLUS technology, with related disposable purchases included.
